Purpose: We sought to characterize the electroclinical features of seizures associated with autoimmune encephalitis and their relevance to outcome. Methods: 19 patients with seizures and autoimmune encephalitis were identified from a database of 100 patients (2008)(2009)(2010)(2011)(2012)(2013)(2014)(2015)(2016)(2017) with autoimmune neurological disorders. Clinical and electroclinical characteristics were collected. Persistent seizures at last follow-up were then correlated with electroclinical features. Results: Status epilepticus (53%) and early intractability to AEDs (median time to second AED 9.5 days) marked the onset of refractory seizures (median number of AEDs 3). Seizure semiology (abdominal (16%), psychic (42%), olfactory (6%) auras), interictal temporal epileptiform discharges (42%), and ictal onset in the temporal region (63%) mirrored radiologic involvement of the medial temporal regions (on MRI in 74% and/or FDG-PET in 75%). In addition, multimodal auras, with somatosensory (26%), autonomic (26%), gustatory (11%), and visual (16%), features were seen in 82% of patients with focal aware seizures, invoking broader involvement of the perisylvian regions. A change in seizure semiology and EEG findings was often seen. Electroclinical features were similar regardless of antibody type, with the exception of the association of faciobrachial dystonic seizures with LGI1 antibodies. Eight patients had medically intractable seizures at last follow-up and were more likely than patients with seizure remission to have generalized tonic-clonic seizures and temporal lobe involvement on the basis of semiological features, interictal EEG and MRI changes. Conclusions: Seizures associated with autoimmune encephalitis exhibit common electroclinical features which show dynamic evolution over time. We propose a role for the temporo-perisylvian regions in their generation.
Introduction
Seizures are commonly seen in autoimmune encephalitis [1] , a heterogeneous group of conditions associated with neural autoantibodies that frequently targets the cell surface and results in channelopathies, hyperexcitability and potential epileptogenicity [2, 3] . A high prevalence of neural autoantibodies has been noted in focal epilepsies, with or without classic features of encephalitis [4] [5] [6] [7] . These advances are noteworthy given targeted immunotherapeutic implications [8] and have been reflected in the most recent ILAE classification, with "immune etiology" listed alongside other classical epilepsy etiologies [9] .
As a result, efforts have been made to define distinct autoimmune electroclinical syndromes, which may guide antibody testing in specific epilepsy populations. Examples include the description of faciobrachial dystonic seizures (FBDS) associated with LGI1 antibodies [10] [11] [12] and medial temporal lobe epilepsy with hippocampal sclerosis (HS) [5, 13] .
While current literature has focused on clinical features upon presentation, important for early recognition and immunotherapy initiation [6] [7] [8] , there is a paucity of data on the evolution of electroclinical features of autoimmune epilepsy over time. A small number of patients with LGI1 antibodies, for example, may continue to experience seizures in the long term [14, 15] . In addition, reliance on antibody testing may result in missed diagnoses in patients with a clinical profile consistent with autoimmune epilepsy who are found to have positive indirect immunohistochemistry methods [1, 16] . Further, electroclinical features and their localization is particularly relevant in patients with ongoing refractory epilepsy being considered for epilepsy surgery. There is therefore a need to characterize electroclinical features spanning the disease course through a syndrome-based approach in addition to an antibody-based analysis.
We sought to describe electroclinical syndromes and their evolution over the course of the disease in a cohort of 19 patients with seizures and autoimmune encephalitis, who underwent video-EEG recordings at various points throughout the illness.
Methods

Patient inclusion
Amongst a database of 100 patients with "Autoimmune Mediated encephalopathy" collected through the Mellen Center at the Cleveland Clinic, 26 patients experiencing seizures over the course of their illness were identified. Amongst these patients, 19 patients had seizures as the exclusive or predominant clinical feature and met criteria for possible autoimmune encephalitis [1] and/or had a disease-causing antibody (LGI1, NMDA-R, GABA-B). Patients without an associated antibody or with a nonspecific antibody (voltage-gated potassium channel (VGKC) without LGI1 or CASPR2, glutamic acid decarboxylase (GAD65), antithyroid) were required to meet diagnostic criteria for autoimmune encephalitis for inclusion. The remainder of the patients in the database were searched in the Epilepsy Center's EEG database to determine they had undergone continuous EEG, and if so, whether subclinical seizures had occurred.
Antibody identification
Antineuronal antibody panels were performed from serum and/or CSF of all patients via commercially available laboratories (Mayo Clinic, Athena Laboratories, ARUP), and included a combination of the following: glutamic acid decarboxylase 65 (GAD65), voltage-gated potassium channel (VGKC), leucine-rich glioma inactivated 1 (LGI1), contactin-associated protein 2 (CASPR2), gamma-aminobutyric acid B (GABA-B), α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA), N-methyl-D-aspartate (NMDA), antineuronal nuclear antibody (ANNA) 1, 2, 3, antiglial nuclear antibody (AGNA) 1, 2, Purkinje-cell antibody (PCA) 1, 2, amphiphysin, anti-Tr antibodies. Panels were performed using indirect immunofluorescence, ELISA and cell-based assays.
Data collection and analysis
Chart review was conducted to collect demographic data, seizure semiology, associated neurologic symptoms, epilepsy risk factors, conventional epilepsy treatment and immunotherapy, neurophysiologic (EEG -interictal and ictal), radiological (MRI, PET) and serologic/CSF (inflammatory markers, neural autoantibody) findings. EEG and seizure semiology were defined throughout the illness. Whenever possible, seizure semiology was confirmed through video-EEG recordings. Continuous video-EEG recordings were available in all patients. Upon follow-up, routine 30 minute EEGs were performed in some patients. EEG was available in 14 patients in the first 3 months of disease onset, 11 patients between 4 months and 11 months, and 9 patients beyond 1 year.
Statistical analysis
First, descriptive statistics were performed for each variable including means, medians and standard deviations for continuous variables and frequencies for categorical variables. Univariate analysis was performed using Wilcoxon rank-sum and Fisher's exact tests to compare antibody positive to antibody negative cases and LGI1 positive to negative cases, as well as patients with persistent seizures at last follow-up to those without. P values less than 0.05 were considered significant.
Standard protocol approvals, registration and patient consents
Institutional Review Boards Ethics approval was obtained. Due to the retrospective nature of the study, consent waiver was granted. e Of note median time to diagnosis was 54 days, which was longer than time to treatment. This discrepancy was caused by the 3 patients who were diagnosed, on average 162 days from symptom onset, but not treated due to patient preference and mild disease severity. f Follow-up was taken as last date of follow-up or death (in 2/7 of patients with persistent seizures). The patient with 0.4 year follow-up died due to uncontrolled status epilepticus 0.4 years from symptom onset. Table 1 highlights patient characteristics. The majority (74%) harbored a positive antibody, the most frequent being LGI1 autoantibodies. Medial temporal abnormalities suggestive of autoimmune limbic encephalitis on MRI and/or FDG-PET were frequently present (74% and 75% respectively).
Results
Patient characteristics
The majority were treated with immunotherapy (84%), with a median time from symptom onset to treatment initiation of 53.5 days.
Epilepsy characteristics
Epilepsy characteristics and seizure semiology are summarized in Table 2 .
Seizure history and response to conventional epilepsy treatment
Seizures were frequently and rapidly refractory to AEDs, with median time to 2nd AED of 9.5 (range 0-365) days and a median number of AEDs of 3 (range 1-6). Of the 66 total AED exposures, drug reaction with eosinophilia and systemic symptoms (DRESS) occurred in one patient treated with levetiracetam, phenobarbital, lacosamide and valproic acid, along with antibiotic polytherapy, requiring treatment with steroids and discontinuation of multiple AEDs.
Status epilepticus marked the onset of disease in 10/19 patients (53%), and was refractory in all but one, meeting criteria for NORSE syndrome [17] . Even in the absence of status epilepticus, seizure burden was high, with multiple daily seizures present in 16/19 (84%) of patients.
Seizure semiology
Subclinical seizures were seen in 58% of patients. Amongst the patients with autoimmune encephalopathy who did not have autoimmune epilepsy (n = 81), 26/81 (32%) had undergone continuous EEG recordings (> 24 hours), and of these, 1/26 (4%) had experienced subclinical seizures.
In addition to faciobrachial dystonic seizures, other types of focal aware motor seizures were seen, consisting of focal clonic, tonic or myoclonic seizures. Focal unaware seizures (47%) consisted of unresponsiveness with or without limb and/or oroalimentary automatisms. Focal aware non-motor seizures consisted of a variety of autonomic, emotional, cognitive and sensory disturbances (referred to as auras in Table 2 and below). 82% of patients with focal aware nonmotor seizures experienced 2 or more of the above disturbances during their seizures. Somatosensory auras (26%) were described as perioral or poorly localized, at times unpleasant. Autonomic seizures (26%) included ictal tachycardia, lightheadedness, flushing and piloerection.
EEG characteristics are outlined in Table 3 .
Interictal EEG
Despite the rapidly refractory seizures and high seizure burden, 47% of patients did not have any interictal epileptiform discharges (IEDs). When present, IEDs were most frequently distributed over the temporal regions (42%). Patients carrying NMDA-R antibodies only (n = 2) exhibited long runs of generalized rhythmic delta, with or without superimposed beta activity.
Ictal EEG
Similarly to distribution of IEDs, EEG seizure onset was frequently over the temporal region (63%), with frequent involvement of the neighboring regions (temporoparietal and/or frontotemporal) (e.g. Fig. 1A ). Non-localizable seizure onset was also seen (38%) (Fig. 1B) , along with seizure onset in at least 2 independent regions or hemispheres (44%).
Change in electroclinical features over time
Seizure semiology and EEG findings changed over time (Table 4) . Despite other ongoing seizure types, GTCs resolved in 7/9 (78%). Amongst 11 patients with focal aware seizures, the types of auras changed in eight (73%). Of the 16 patients with recorded EEG seizures, change in ictal onset distribution (shifting regions or hemispheres) was noted in five (31%).
Electroclinical characteristics per antibody groups
As expected, FBDS were only seen with LGI1 antibodies only (4/6 vs 0/13, p = 0.004), accounting for the higher number of seizures with IEDs -interictal epileptiform discharges. LPDs-lateralized periodic discharges. a Only recorded in patients with NMDA-R antibodies.
non-localizable onset (subtle and diffuse electrodecremental pattern) (4/6 vs 2/13, p = 0.036). There were no significant differences in electroclinical features between the antibody positive and negative groups. All comparisons are shown in Supplementary Table S1 .
Outcome
Eight of 19 patients (42%) were still experiencing seizures at last follow-up or at time of death, without a history of sustained seizure remission or latent period between acute presentation and chronic seizures. However, AED requirement decreased from median of 3 AEDs tried over the course of the illness to 2 AEDs at last follow-up (range 0-4).
One patient underwent a standard nondominant anterior temporal lobectomy 5 years after disease onset, following a video-EEG evaluation that showed independent bitemporal EEG seizures with higher burden of seizures from the right temporal region. Prior to surgery, brain MRI did not show any areas of hyperintensity or edema suggestive of inflammation. No updated CSF studies were performed prior to epilepsy surgery. Furthermore, no antineuronal antibodies had been identified in serum or CSF upon initial presentation with limbic encephalitis, thus this was not repeated in the setting of presurgical evaluation. Seizures recurred postoperatively but with > 50% improvement in seizure frequency. Pathology revealed gliosis, amygdala hamartoma and perivascular inflammatory infiltrates (> 90% CD3 positive T cells, equal CD4 and CD8 positive) in the amygdala and hippocampus (Fig. 2) . Fig. 1 . Ictal EEG. A. Buildup of rhythmic sharp waves is seen over the left temporo-parietal region (note involvement of the parasagittal chain early in the ictal pattern, see arrows). Temporal ictal patterns were noted to extend beyond the temporal electrodes in the majority of patients. B. Generalized attenuation, preceded by high amplitude slow activity maximum over the right frontocentral and vertex region, is associated with brief contraction of the left arm (faciobrachial dystonic seizures), with associated EMG artifact. Each asterisk corresponds to a seizure. Antero-posterior longitudinal bipolar montage. High pass filter 1.53 Hz, low pass filter 70 Hz. All comparisons are shown in Supplementary Table S2 .
Discussion
This study describes the electroclinical features of a cohort of 19 patients with seizures and autoimmune encephalitis and their relationship to outcome, through detailed electroclinical data spanning several months of the disease course. Follow-up period was longer than that reported in previous cohorts [6] [7] [8] 18] , providing insights into the chronic aspects of a proportion of these patients. In addition, all patients had undergone prolonged video-EEG recordings, enabling a detailed analysis of their complex epilepsy.
Severe and refractory seizures
Early intractability to AEDs, with or without status epilepticus, marked the onset of epilepsy in the majority of cases. Previously reported autoimmune epilepsy cohorts have similarly exhibited rapid onset of seizures [8, 18] and treatment with high number of AEDs, with rare seizure freedom when AEDs were used alone [19] . The high number of AEDs and early addition of a 2 nd AED similarly supports AED drug resistance, while the majority of patients were seizure free at last follow-up (58%). There are two potential explanations for this (not mutually exclusive): 1) the addition of immunotherapy to AED led to seizure freedom, 2) the natural history of autoimmune epilepsy is that of high seizure burden at onset, with wind-down and improvement in seizure frequency in the majority of cases. Indeed, 3 patients were not treated with immunotherapy, 2 of which became seizure free (67%), while of the 16 patients treated with immunotherapy, 9 became seizure free (56%). Of note, immunotherapy was not administered in these 3 patients due to a milder phenotype or patient preference, such that these similar rates of seizure freedom are likely reflective of the pathology being more severe in the group that received immunotherapy. We also found a high incidence of subclinical seizures (58%) in this cohort, likely specific to the epilepsy predominant phenotype of autoimmune encephalitis given the comparatively low rate of subclinical seizures in the remainder of the patients with autoimmune encephalitis (4%). This finding echoes the findings of frequent subclinical seizures in LGI1-antibody associated encephalitis involving the temporal [20] , frontotemporal, or frontocentral regions [21] . The use of continuous EEG to detect subclinical seizures is therefore necessary in patients with autoimmune epilepsy to determine an accurate seizure burden, even when clinical seizures are evident. The relevance of treatment of subclinical seizures in addition to clinical seizures to outcome (in cognitive and seizure domains) remains to be determined in longitudinal outcome studies.
A temporo-perisylvian model
A multitude of multimodal auras (not only experiential, abdominal, olfactory and but also somatosensory, gustatory and visual) and prominent ictal autonomic activation were seen together with seizures with impaired awareness and/or automatisms and were present regardless of antibody positivity and type. We hypothesize a role for not only temporal, but also perisylvian (insular and opercular) regions as final common pathways in the dynamic nature of these epilepsies.
Postencephalitic epilepsy of various etiologies has been associated with auditory auras of varying complexity, but also gustatory and somatosensory auras [22] , extending beyond that seen in classic medial temporal lobe epilepsy to the perisylvian region. Auditory auras have been described in adult-onset Rasmussen's encephalitis [23] , along with laryngeal constriction, facial flushing and somatosensory disturbance [24] , in line with FLAIR signal change and atrophy that is maximal in the perisylvian regions [25] . Gillinder et al. [26] similarly reported the frequent nature of multimodal auras evoking the perisylvian region in a cohort of antibody-positive chronic epilepsy patients. Magnetoencephalography studies demonstration of perisylvian dipole localization [27, 28] and voxel-based volumetric analyses revealing opercular enlargement [29] provide further support for perisylvian involvement.
The concept of temporo-perisylvian epilepsies characterized by extent of epileptogenic zone beyond the temporal lobe to its neighboring regions [30] may therefore apply to this patient population. The lack of concordance between prevalence of hippocampal sclerosis versus epilepsy in follow-up of LGI1 encephalitis [15, 21, 31, 32] , and in this cohort, together may indicate that neurodegeneration and reorganization of the hippocampus may not be sufficient to generate these complex epilepsies. Perisylvian regions may therefore be susceptible to immunemediated epileptogenesis, in addition to the medial temporal structures. Other semiological features, such as the motor seizure types, may represent additional involvement of the basal ganglia (such as in faciobrachial dystonic seizures) and/or motor cortex (such as in simple clonic seizures).
Electroclinical features as predictors of postencephalitic epilepsy
In addition to demonstrating a predictable spectrum of electroclinical features, we showed an association between persistence of seizures (or "postencephalitic epilepsy") and evidence of temporal lobe involvement, on the basis of focal unaware seizures, interictal temporal lobe involvement, and medial temporal MRI changes in the acute setting. Presence of GTCs was also associated with persistent seizures. These findings highlight the potential for electroclinical features to be integrated in predictive models of not only diagnosis, such as the recently developed antibody-prevalence in epilepsy (APE) score [6, 7] , but also of outcome.
Implications for epilepsy surgery
The utilization of a deeper understanding of electroclinical features for an accurate localization of autoimmune epilepsies has implications for the epilepsy surgery pathway and its odds of success. First, the involvement of the perisylvian regions in additional to the medial temporal structures may in part explain the poor success with anterior temporal lobectomy in this patient population [33] . Second, multiple independent regions of EEG seizure onset were seen in a significant proportion (44%) of this cohort, and were at times bilateral, such as in the case of the patient who underwent a temporal lobectomy (Fig. 2) . This parallels the multiple seizure types seen in this cohort and others [18, 21] , and could indicate the presence of independent multifocal regions of epilepsy. These two factors may be mitigated by the use of invasive recordings to better map the epileptogenic zones.
An additional factor associated with seizure recurrence may be a dynamic epileptogenic zone, supported by neuropathological evidence of perivascular lymphocytic infiltrates several years after the onset of epilepsy [33, 34] , as noted in one patient in our cohort (Fig. 2) . Furthermore, patients with persistent seizures had no seizure-free period after the acute phase, such that it may be challenging in clinical practice to distinguish between a phase of acute immune-mediated epilepsy, considered potentially responsive to immunotherapy, and a so-called "postencephalitic epilepsy" [35] . Change in semiological and EEG features was also noted in a proportion of patients, including change in aura types and ictal EEG onset distribution, adding to the dynamic nature to the seizures, consistent with previous reports of variations in seizure semiology [18] . These findings may imply ongoing smoldering inflammation with recruitment of various brain regions over time, rather than an initial immune-mediated insult and subsequent static epilepsy.
It is therefore of utmost importance to recognize the limitations of using clinical stability and epilepsy duration to rule out the presence of active inflammation. CSF studies and repeat antibody assays prior to epilepsy surgery may provide alternative medical treatment options prior to planning an irreversible, potentially cognitively morbid surgical intervention.
Limitations
Limitations of our study include its retrospective chart review methodology and heterogeneous patient population (different antibody types and antibody negative cases included), which was intended to reflect and inform clinical practice. In addition, lack of patients with certain antibodies associated with epilepsy (AMPA-R, GABA-A, glycine-R) and small numbers of patients with GAD65 and GABA-B receptor antibodies may limit extrapolation to this population. While antibody negative patients exhibited similar clinical features, the lack of biological confirmation of underlying immune mechanisms may shed doubt on the underlying etiology. Our center did not have access to further confirmatory techniques including indirect immunohistochemistry or live cultured neuron techniques. Of note, all antibody negative patients met diagnostic criteria for autoimmune encephalitis through clinical findings and supportive ancillary testing (MRI, CSF) [1] . The lack of clinical distinction between antibody positive and negative groups supports a unifying epilepsy etiology in this cohort. Finally, patients were identified through an autoimmune disorders database therefore weighing the cohort toward typical autoimmune syndromes (such as limbic encephalitis) as opposed to isolated epilepsy. However, 5/19 of patients did not have overt encephalopathy suggestive of an encephalitic process, expanding the clinical spectrum to the outpatient setting.
Conclusions
This study highlights the dynamic electroclinical characteristics of seizures in the setting of autoimmune encephalitis and their potential relevance to persistent seizures after the acute encephalitic illness and their localization. Future studies of larger patient cohorts with ongoing follow-up will enable further understanding of the complex nature of their epilepsies, which may in turn improve patient selection for antibody testing and disease modifying therapeutic trials.
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